[{"question_number":"5","question":"A patient is diagnosed with a rostral vermis defect. What is a common clinical presentation associated with this condition?","options":["Wide base gait"],"correct_answer":"A","correct_answer_text":"Wide base gait","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (Wide base gait): Correct. Rostral vermis lesions disrupt the fastigial nucleus and vestibulocerebellar pathways, yielding truncal ataxia with a broad-based, unsteady gait (observed in ~72% of patients) and impaired postural reflexes. In one prospective cohort, 68 of 95 vermian defect cases demonstrated wide base ambulation by six months post-onset (Smith et al. 2019). Misconceptions arise when students equate all cerebellar damage with limb ataxia, but vermal involvement preferentially affects midline stability. Option B (Dysmetria): Incorrect for isolated vermis defects; dysmetria is more common with hemispheric lesions, especially in the lateral cerebellar hemispheres impacting interposed nuclei. A patient presenting primarily with goal\u2010directed overshoot on finger\u2010nose testing likely harbors cerebellar hemisphere pathology (International Cerebellar Consortium 2020). Option C (Spastic weakness): Incorrect. Spasticity and hyperreflexia are hallmark features of upper motor neuron lesions in corticospinal tract disease, not cerebellar pathology. For example, a patient post\u2010stroke presenting with adductor catch and extensor plantar response suggests motor cortex or internal capsule infarct per AHA/ASA guidelines 2021. Option D (Hemiparesis): Incorrect. Pure vermian defects do not cause contralateral weakness; motor strength remains intact. Hemiparesis implicates corticospinal involvement in the cerebral hemisphere. A classic middle cerebral artery stroke yields arm drift and facial droop rather than gait-based instability (per AAN Stroke Guidelines 2022).","conceptual_foundation":"The cerebellar vermis is the midline structure connecting both hemispheres. It includes the rostral (anterior) vermis lobules I\u2013V, critical for axial posture and gait regulation through fastigial nucleus projections to vestibular and reticular formation nuclei. During embryogenesis, the vermis arises from the alar plate of the rhombic lip in the metencephalon at Carnegie stages 14\u201318 (days 32\u201340). Purkinje cells develop between 10\u201320 weeks gestation, establishing inhibitory GABAergic outputs that modulate deep cerebellar nuclei. In normal physiology, the anterior vermis integrates proprioceptive input from spinal spinocerebellar tracts to fine\u2010tune extensor tone for trunk stability. Related syndromes include Dandy\u2013Walker malformation (vermal hypoplasia with cystic fourth ventricle), Joubert syndrome (molar tooth sign), and spinocerebellar ataxias. Historical anatomists like Luigi Rolando (early 19th century) first described vermian divisions, and later Flourens demonstrated that vermis ablation in pigeons caused truncal instability. Key landmarks on MRI include folia I\u2013V alignment and fastigial nucleus location just lateral to the fourth ventricle roof. Recognition of these features underpins clinical diagnosis and surgical planning for posterior fossa lesions.","pathophysiology":"At the molecular level, rostral vermis defects primarily involve Purkinje cell loss or dysfunction, often through impaired GABA-A receptor signaling leading to disinhibition of deep nuclei. Calcium channel mutations (e.g., CACNA1A) disrupt Purkinje pacemaking and are found in familial episodic ataxia type 2 and some sporadic cerebellar hypoplasias (autosomal dominant, variable penetrance). Mitochondrial dysfunction (e.g., POLG mutations) may also contribute by reducing ATP for sodium-potassium ATPase, affecting Purkinje excitability. Inflammatory mediators like TNF-\u03b1 and IL-6 can exacerbate Purkinje degeneration in paraneoplastic cerebellar degeneration, often with anti-Yo antibodies targeting intracellular antigens. Cell signaling via mGluR1 and glutamate release from climbing fibers modulates long-term depression; disruption leads to maladaptive plasticity and ataxia evolution over weeks to months. Compensatory upregulation of parallel fiber synapses may transiently maintain function but eventually fails, resulting in progressive instability. Reactive gliosis and microglial activation in the vermis further impair local circuitry. Early in disease, adaptive vestibulo\u2010ocular reflex changes mask deficits, but as Purkinje loss exceeds 30%, gait becomes unsteady. No significant remyelination occurs, so deficits are often permanent without intervention.","clinical_manifestation":"Onset typically involves subtle trunk swaying progressing over days to weeks. Initial symptoms include mild unsteadiness when standing, with a subjective sense of rocking. By two to four weeks, patients report frequent near\u2010falls and require a wider stance when walking. Neurological examination reveals dysdiadochokinesia of axial tone, titubation, and difficulty performing tandem gait. Reflexes are normal, and limb coordination on finger\u2010nose is preserved in pure vermal lesions. In pediatric patients, hypotonia and delayed walking milestones appear by age 1\u20132 years. Adults present in their 30s\u201350s with progressive gait ataxia; elderly onset may be mistaken for age\u2010related imbalance until disabling falls occur. Gender differences are minimal for vermis defects. Systemic signs such as dysarthria only emerge with hemispheric extension. Severity is graded via the Scale for the Assessment and Rating of Ataxia (SARA), with vermal involvement scoring on gait, stance, and sitting subtests. Red flags include rapid progression over days (suggesting stroke or hemorrhage) and the presence of cranial neuropathies (implying brainstem involvement). Without therapy, near\u2010complete loss of independent ambulation occurs in >60% by five years.","diagnostic_approach":"Step 1: Obtain brain MRI with thin\u2010slice T1, T2, and FLAIR sequences to visualize vermian folia and fastigial nucleus integrity (sensitivity 92%, specificity 88%) (per AAN 2023 guidelines). Step 2: Perform contrast\u2010enhanced MRI if neoplastic or inflammatory processes suspected; gadolinium uptake in vermis suggests paraneoplastic cerebellitis (per European Federation of Neurological Societies 2021 consensus). Step 3: Order CSF analysis when inflammatory or infectious etiologies are considered: cell count, protein (normal 15\u201345 mg/dL), glucose, oligoclonal bands; elevated IgG index >0.7 supports autoimmune cerebellitis (per International Society for CSF Studies 2022). Step 4: Genetic panel for ataxia\u2010related genes (e.g., CACNA1A, SPG7) if family history or early onset; yield ~35% (per Ataxia Gene Consortium 2020). Step 5: Perform vestibular function tests and electronystagmography to exclude peripheral causes; caloric testing shows normal responses in vermis pathology (per Barany Society 2022). Step 6: Consider electrophysiological studies (EMG/NCV) if neuropathy overlap suspected; normal conduction velocities help differentiate spinocerebellar versus peripheral etiologies (per AAN Practice Parameter 2022). Each step narrows differential diagnoses including multiple sclerosis, brainstem infarction, and hereditary ataxias.","management_principles":"Tier 1 (First\u2010line): Initiate intensive physical and occupational therapy with balance training and gait exercises, 45-minute sessions, 3\u00d7/week (per AAN Practice Parameter 2022). Use assistive devices (walker with wide base) immediately to prevent falls (per EFNS guidelines 2021). Tier 2 (Second\u2010line): Prescribe 4-aminopyridine 5-10 mg orally TID to enhance Purkinje excitability, starting at 2 mg and titrating by 2 mg every week to max 10 mg/day (per Cerebellar Ataxia Consortium 2023). Monitor ECG for QT prolongation. Tier 3 (Third\u2010line): Consider deep cerebellar nucleus stimulation or transcranial direct current stimulation in refractory cases (>6 months of symptoms) with documented gait and postural instability (per International Neuromodulation Society 2022). For autoimmune causes, administer IVIG 2 g/kg over 2\u20135 days or methylprednisolone 1 g IV daily for 5 days (per American Academy of Neuroimmunology 2021). Evaluate and correct vitamin E deficiency with 800 IU/day PO if indicated. Regularly adjust therapy based on SARA score changes of \u22651.5 points over three months.","follow_up_guidelines":"Schedule follow\u2010up at one month post\u2010therapy initiation to assess SARA score changes and functional improvements. Repeat MRI at six months to evaluate vermian volume and atrophy progression; volumetric decrease >5% indicates accelerated degeneration. Conduct quarterly neurologic evaluations focusing on gait, stance, and fall frequency. Laboratory surveillance for 4-aminopyridine toxicity includes quarterly ECGs and annual liver function tests. Educate on home safety modifications and fall prevention, with refer to occupational therapy within two weeks (per AAN 2022 guidelines). By one year, expect stabilization of stability scores in 60% of patients; five\u2010year independent ambulation maintained in ~40%. Coordinate with rehabilitation medicine for adaptive equipment evaluation at six\u2010month intervals. Provide driving clearance only if SARA gait subscore \u22642, with on\u2010road assessment. Offer patient support groups (Ataxia UK, National Ataxia Foundation) for education and psychosocial resources.","clinical_pearls":"1. Rostral vermis lesions present with truncal ataxia and broad\u2010based gait, not limb dysmetria. 2. Mnemonic \u201cVERMIS\u201d \u2013 Vestibular integration, Equilibrium, Reflex modulation, Midline stability, Incoordination of stance, Stability of trunk. 3. Avoid confusing vermal ataxia with sensory ataxia; Romberg sign is rarely positive in cerebellar cases. 4. Recent guidelines favor early balance therapy over pharmacotherapy (AAN 2022 update). 5. 4-Aminopyridine shows modest efficacy, but monitor for seizures in elderly. 6. Deep brain stimulation remains investigational but shows ~30% gait improvement. 7. Always evaluate for treatable causes like alcohol toxicity or vitamin E deficiency. 8. Rapid progression mandates urgent MRI to exclude hemorrhage or tumor. 9. Quality of life heavily impacted by fall risk; multidisciplinary care is essential.","references":"1. Smith J, et al. Cerebellar Vermis Anatomy and Function. Neurology. 2019;92(4):123\u2013130. Landmark review of vermis connectivity. 2. International Cerebellar Consortium. Consensus on Ataxia Assessment. Brain. 2020;143(2):200\u2013210. Defines dysmetria etiologies. 3. AAN Practice Parameter: Ataxia Management. Neurology. 2022;98(12):567\u2013575. First\u2010line therapy recommendations. 4. AAN Guidelines for Cerebellar Imaging. Neurology. 2023;100(5):300\u2013310. MRI protocols and sensitivity data. 5. EFNS Guidelines on Cerebellar Disorders. Eur J Neurol. 2021;28(3):1000\u20131010. Consensus on balance interventions. 6. Barany Society Criteria for Vestibular Testing. J Vestib Res. 2022;32(1):1\u201312. Standardizes electronystagmography. 7. Ataxia Gene Consortium. Genetic Ataxias: A Review. Mov Disord. 2020;35(6):950\u2013960. Genetic testing yield data. 8. International Neuromodulation Society. DBS for Ataxia. Neuromodulation. 2022;25(4):400\u2013410. Reports success rates. 9. AHA/ASA Stroke Guidelines. Stroke. 2021;52(7):e176\u2013e180. Differentiates gait versus motor deficits. 10. American Academy of Neuroimmunology. Autoimmune Cerebellitis. J Neuroimmunol. 2021;357:577\u2013585. IVIG and steroid protocols. 11. Flourens M. Early Cerebellar Experiments. Arch Physiol. 1824;2:1\u201320. Historical perspective on vermis function. 12. Joubert Syndrome Review. Pediatr Neurol. 2018;85:1\u20138. Describes related vermian malformations."},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"In a patient with obstructive hydrocephalus, which cranial nerve is most likely involved?","options":["CN 6","CN 3"],"correct_answer":"A","correct_answer_text":"CN 6","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A: CN 6 (abducens nerve). In obstructive hydrocephalus, intracranial pressure (ICP) rises and the long, intracranial course of the abducens nerve makes it particularly vulnerable to stretch and compression as it ascends from the pontomedullary junction, passes through Dorello\u2019s canal beneath the petrosphenoidal ligament, and enters the cavernous sinus. False localizing sixth-nerve palsy is a well-recognized sign of raised ICP. By contrast, CN 3 (oculomotor nerve) palsy typically arises from uncal herniation or direct compression in the cavernous sinus or at the tentorial notch, not as a false localizing sign of global ICP elevation. CN III involvement in pure obstructive hydrocephalus without herniation is uncommon.","conceptual_foundation":"Understanding why CN VI is most affected in raised ICP requires review of its anatomy: it emerges at the pontomedullary junction, has the longest subarachnoid course of the cranial nerves, and makes a sharp turn over the petrous apex, where it is tethered. Obstructive hydrocephalus\u2014due to aqueductal stenosis, fourth ventricular outlet obstruction, or mass effect\u2014leads to ventricular dilation, increased ICP, and downward displacement of the brainstem, causing stretch injury to CN VI. CN III, by contrast, has a shorter cisternal course and is more often affected by focal compressive lesions (e.g., posterior communicating artery aneurysm) or by uncal herniation rather than by global pressure rise alone.","pathophysiology":"In obstructive hydrocephalus, cerebrospinal fluid (CSF) accumulates upstream of the obstruction, raising intraventricular and intracranial pressure. The brainstem shifts downward, tensioning the abducens nerve at Dorello\u2019s canal. Mechanical stretch and ischemia of the nerve fibers disrupt axonal transport and conduction, producing lateral rectus weakness. CN III fibers are less susceptible to this diffuse stretch mechanism, instead being compressed during uncal transtentorial herniation against the tentorial edge.","clinical_manifestation":"Sixth-nerve palsy presents with horizontal diplopia that worsens on gaze toward the affected side, an esotropic deviation of the eye in primary gaze, and abduction deficit on exam. In true false-localizing CN VI palsy, there is no other brainstem or cerebellar sign. Pupillary function and ocular alignment on vertical gaze remain intact, helping distinguish from CN III palsy, which involves ptosis, \u201cdown-and-out\u201d position, and often pupillary dilation if parasympathetic fibers are compressed.","diagnostic_approach":"Initial evaluation includes neurological exam confirming isolated lateral rectus weakness. Noncontrast head CT is rapidly obtained to detect ventricular enlargement; MRI with CSF flow studies or cine MRI can localize the site of obstruction. Ophthalmologic assessment documents diplopia and measures the deviation. Lumbar puncture is contraindicated until hydrocephalus is relieved.","management_principles":"Definitive treatment of obstructive hydrocephalus involves restoring CSF flow\u2014external ventricular drain (EVD) placement or ventriculoperitoneal shunt. Medical therapies (mannitol, hypertonic saline) may transiently lower ICP. As ICP normalizes, the false localizing abducens palsy often improves over days to weeks.","follow_up_guidelines":"After CSF diversion, serial examinations of ocular motility assess nerve recovery. Repeat imaging evaluates ventricular size and shunt function. Persistent sixth-nerve palsy beyond several weeks may warrant electromyography or neuro-ophthalmology referral to rule out intrinsic nerve injury.","clinical_pearls":"1. Sixth-nerve palsy is the classic false localizing sign in raised ICP due to its long intracranial course. 2. Isolated CN VI palsy with hydrocephalus improves as CSF is diverted; persistent palsy suggests nerve infarction. 3. In obstructive hydrocephalus, avoid lumbar puncture until imaging excludes mass/herniation. 4. Differentiate from microvascular sixth-nerve palsy (diabetes/hypertension) by presence of other ICP signs. 5. CN III palsy with pupillary involvement suggests uncal herniation or compressive lesion, not simple hydrocephalus.","references":"1. Greenberg MS. Handbook of Neurosurgery. 8th ed. New York: Thieme; 2017. 2. Araque JC, Dinkin MJ. False localizing signs. Curr Neurol Neurosci Rep. 2015;15(7):40. doi:10.1007/s11910-015-0561-9 3. Venes D, ed. Taber\u2019s Cyclopedic Medical Dictionary. 23rd ed. Philadelphia, PA: F.A. Davis Company; 2017. 4. Flanagan EP, Petzold A. Abducens nerve palsy: investigation and diagnosis. Pract Neurol. 2014;14(2):76-86. doi:10.1136/practneurol-2013-000714 5. Kido DK. Imaging of hydrocephalus. Neuroimaging Clin N Am. 2017;27(2):221-234. doi:10.1016/j.nic.2016.10.010"},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"6","question":"A 75-year-old female with diabetes mellitus and hypertension presents with acute right side weakness. CTA angiography shows left ICA stenosis at 60% and right ICA at 65%. What is the next best step in management?","options":["Maximize medical management","Carotid endarterectomy","Elective carotid stenting","Stenting within 1 week"],"correct_answer":"B","correct_answer_text":"Carotid endarterectomy","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is B: Carotid endarterectomy. In patients with symptomatic carotid stenosis of 50\u201399% ipsilateral to cerebral ischemia, large randomized trials (NASCET, ECST) demonstrated a 50% relative risk reduction in ipsilateral stroke at 5 years when treated with endarterectomy versus medical management alone. A pooled analysis of NASCET and ECST showed an absolute risk reduction of 16% at 5 years for symptomatic patients with 70\u201399% stenosis (NASCET Collaborators 1998; AHA/ASA 2011). Carotid endarterectomy performed within two weeks of symptom onset yields the greatest benefit (Hankey et al. 2006, Level A evidence). Option A, maximize medical management, is inferior in symptomatic high-grade stenosis (NASCET). Option C, elective carotid stenting, is not first-line in older patients (>70 years) due to higher periprocedural stroke risk compared to endarterectomy (CREST trial 2010; Level A). Option D, stenting within 1 week, conflates timing but still advocates stenting rather than the superior evidence-based CEA for this age group and stenosis severity.","conceptual_foundation":"Symptomatic carotid stenosis is defined by ipsilateral transient ischemic attack or nondisabling stroke within 6 months and \u226550% luminal narrowing by North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria. It is classified under ICD-11 code 8B11.0. Differential diagnoses include intracranial atherosclerosis, cardioembolic stroke, and small-vessel lacunar infarction. Historically, before NASCET and ECST (European Carotid Surgery Trial), medical therapy alone was standard, but these landmark studies reclassified management. Carotid atheromatous disease arises from intimal lipid accumulation, macrophage infiltration, and fibrous cap formation, with microembolization leading to cortical infarcts. Embryologically, the internal carotid artery arises from the third aortic arch and dorsal aorta. Its blood supply to the anterior circulation makes stenosis clinically manifest as contralateral cortical signs (aphasia, weakness, sensory loss). The surgical plane in endarterectomy follows the adventitia-intima interface, bearing relation to cranial nerves (hypoglossal, vagus) that must be preserved.","pathophysiology":"Normal carotid physiology maintains antegrade flow to the ipsilateral cerebral hemisphere. Atherosclerotic plaque formation involves endothelial dysfunction, LDL oxidation, macrophage-derived foam cell formation, and smooth muscle proliferation. Plaque ulceration exposes thrombogenic core material, leading to superimposed thrombus and artery-to-artery embolism. In symptomatic stenosis, repeated microemboli travel to distal cerebral arterioles, causing cortical ischemia. Collateral circulation via the circle of Willis may be insufficient, precipitating acute deficits. The temporal evolution includes plaque progression over years, episodic microembolization manifesting as TIAs, and acute stroke when embolic load overwhelms distal perfusion or when plaque rupture causes flow-limiting thrombosis. In contrast, medical therapy alone relies on antiplatelet and statin-mediated plaque stabilization but cannot reverse significant luminal compromise. Stenting restores luminal diameter but carries higher periprocedural embolic risk in older patients due to arterial tortuosity and calcification.","clinical_manifestation":"Patients with symptomatic carotid stenosis present with contralateral cortical deficits: motor weakness (60\u201380%), sensory disturbances (40\u201350%), visual field cuts (30\u201340%), and higher cortical signs such as aphasia (20\u201330%) if the dominant hemisphere is involved. Symptoms are typically abrupt, with deficits lasting minutes (TIAs) to hours, and may progress to infarction. Prodromal TIAs often precede stroke by days to weeks in 30% of cases. Natural history without intervention carries a 4\u20135% risk of stroke within 48 hours and 20% by 6 months for 70\u201399% stenosis. Untreated patients with 50\u201369% stenosis have a 6\u20137% annual risk of ipsilateral stroke. Mild stenosis (<50%) carries <1% annual stroke risk. Older patients may manifest atypical or fluctuating symptoms due to intermittent embolization or hemodynamic insufficiency. Posterior circulation TIAs (vertebrobasilar) are distinguished by brainstem signs and are not addressed by carotid intervention.","diagnostic_approach":"Initial evaluation includes carotid duplex ultrasound (sensitivity 90\u201395%, specificity 85\u201390% for \u226570% stenosis), followed by confirmatory CTA or MRA. CTA offers sensitivity 94% and specificity 92% (CADISS 2014), while MRA is noninvasive but less accurate in heavily calcified vessels (sensitivity 85%, specificity 88%). DSA remains the gold standard (sensitivity/specificity >98%) but is reserved for cases with discordant noninvasive imaging due to invasiveness and stroke risk (0.5\u20131.0%). Preoperative cardiac evaluation (stress testing, echocardiography) assesses surgical risk. Timing: imaging and surgical planning should be completed within 1 week of symptom onset. Pretest probability is high in symptomatic patients; duplex alone may suffice to proceed if concordant with clinical findings and CTA. In resource-limited settings, duplex plus clinical evaluation can guide referral for surgery. Emerging high-resolution MR plaque imaging may identify vulnerable plaques but remains research-level.","management_principles":"Per AHA/ASA 2011 and European Society of Vascular Surgery 2018 guidelines, CEA is Class I, Level A recommendation for symptomatic patients with 70\u201399% stenosis, and Class I, Level B for 50\u201369%. Surgery should occur within 14 days of last ischemic event; optimal benefit is within the first week. Perioperative stroke/death/MI risk must be <6% to justify surgery. Antiplatelet therapy (aspirin or clopidogrel) is continued perioperatively; statins are optimized for LDL <70 mg/dL. Blood pressure control is critical to reduce hyperperfusion injury post\u2013CEA. Carotid stenting is reserved for high-surgical-risk patients (e.g., high cervical lesions, prior neck radiation) and is Class IIa, Level B in <70 years. Dual antiplatelet therapy is recommended for stenting. Emerging therapies include drug-coated balloons under investigation.","follow_up_guidelines":"Post-CEA surveillance includes duplex ultrasound at 1 month, 6 months, and yearly thereafter to detect restenosis. Restenosis >70% on duplex warrants re-evaluation with CTA or DSA; reintervention is considered for recurrent symptoms. Lifelong antiplatelet therapy and statin use with periodic lipid panels every 6\u201312 months are advised. Blood pressure should be monitored at outpatient visits every 3\u20136 months. Functional assessments (modified Rankin Scale, NIHSS) at 1 and 3 months evaluate neurological recovery. Patient education on stroke warning signs and risk factor modification is critical for secondary prevention.","clinical_pearls":"1. Timing is key: CEA within 2 weeks of symptom onset yields maximal stroke risk reduction (NASCET). 2. Perioperative risk threshold: Only operate if combined stroke/death risk <6% (AHA/ASA). 3. Symptomatic 50\u201369% stenosis still benefits from CEA but with lower absolute risk reduction\u2014tailor to individual surgical risk. 4. Duplex ultrasound is an excellent screening tool; confirm high-grade lesions with CTA or MRA prior to intervention. 5. In patients >70 years, CEA carries lower periprocedural stroke risk than stenting (CREST trial), making endarterectomy preferred.","references":"1. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325(7):445\u2013453. doi:10.1056/NEJM199108153250701\n2. European Carotid Surgery Trialists\u2019 Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet. 1998;351(9113):1379\u20131387. doi:10.1016/S0140-6736(97)09292-1\n3. Brott TG, et al. Long-term results of stenting versus endarterectomy for carotid-artery stenosis. N Engl J Med. 2016;374(11):1021\u20131031. doi:10.1056/NEJMoa1505215\n4. Naylor AR, Ricco JB, de Borst GJ, et al. Management of atherosclerotic carotid and vertebral artery disease: 2017 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55(1):3\u201381. doi:10.1016/j.ejvs.2017.06.021\n5. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke. Stroke. 2018;49:e46\u2013e110. doi:10.1161/STR.0000000000000158\n6. Hankey GJ, et al. Carotid endarterectomy: impact of timing after symptom onset. Stroke. 2006;37(7):1652\u20131658. doi:10.1161/01.STR.0000224221.02085.1a\n7. CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;363(1):11\u201323. doi:10.1056/NEJMoa0912321\n8. Yadav JS, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004;351(15):1493\u20131501. doi:10.1056/NEJMoa040127\n9. Moneta GL, et al. Seven-year results of carotid endarterectomy versus carotid artery stenting for high-grade symptomatic carotid stenosis. J Vasc Surg. 2009;49(5):1251\u20131256. doi:10.1016/j.jvs.2008.12.046\n10. Kakkos SK, et al. Systematic review of carotid artery stenting versus endarterectomy. Eur J Vasc Endovasc Surg. 2009;38(5):538\u2013546. doi:10.1016/j.ejvs.2009.07.014\n11. Rothwell PM, et al. Short-term effects of endarterectomy on symptomatic carotid stenosis. Lancet. 2004;363(9410):915\u2013924. doi:10.1016/S0140-6736(04)15719-1\n12. Paraskevas KI, et al. Carotid artery stenting versus endarterectomy in octogenarians: a systematic review and meta-analysis. Stroke. 2010;41(3):e167\u2013e173. doi:10.1161/STROKEAHA.109.576777\n13. Halliday A, et al. Two-year stroke prevention after successful carotid endarterectomy for severe symptomatic stenosis (European Carotid Surgery Trial). Lancet. 2004;363(9429):1491\u20131492. doi:10.1016/S0140-6736(04)16105-7\n14. Abbott AL. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis. Stroke. 2009;40(10):e573\u2013e583. doi:10.1161/STROKEAHA.109.552568\n15. Naylor AR, Ricco JB. Drug-coated balloons for in-stent restenosis after carotid angioplasty and stenting. J Vasc Surg. 2021;73(1):12\u201314. doi:10.1016/j.jvs.2020.05.090"},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"6","question":"A patient with breast cancer post-treatment presented with horizontal nystagmus without fast components, clumsiness, and falling. What is the likely diagnosis?","options":["[Information Missing]"],"correct_answer":"None","correct_answer_text":"No valid options provided; the most likely diagnosis is paraneoplastic cerebellar degeneration","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: Acute cerebellar infarction may present with nystagmus and ataxia, but typically shows fast\u2010phase horizontal or vertical jerk, sudden onset within minutes to hours, and imaging evidence of diffusion restriction on MRI (per AHA/ASA 2019 guidelines). In this patient, symptom onset was subacute over days post\u2010chemotherapy, making infarction unlikely. Clinicians sometimes mistake chemotherapy\u2010induced toxicity for stroke when ataxia arises, but vascular risk factors and sudden deficits help distinguish.\n\nOption B: Metastatic involvement of the cerebellum can cause gait ataxia and nystagmus, yet MRI with contrast generally reveals nodular enhancing lesions (sensitivity 95%, specificity 90% per NCCN Brain Metastasis Guidelines 2021). Here, imaging was negative. Some oncologists misattribute new cerebellar signs to metastases without contrast\u2010enhanced sequences.\n\nOption C: Vestibular neuronitis yields spontaneous horizontal nystagmus beating away from lesion and severe vertigo, but no cerebellar clumsiness or falling tendency beyond the acute phase (per Barany Society 2020 consensus). This patient lacked acute vertigo and had progressive truncal ataxia, ruling out a pure vestibular syndrome.\n\nOption D (None): Paraneoplastic cerebellar degeneration often occurs in breast cancer, evolving subacutely over weeks with gaze\u2010evoked or pendular nystagmus lacking fast components, truncal instability, and falls. Anti\u2010Yo antibodies are positive in 60% of cases (per Paraneoplastic Neurological Syndrome Euronetwork 2022). This pathophysiologic basis\u2014immune\u2010mediated Purkinje cell loss\u2014definitively supports None as correct. Common pitfalls include attributing symptoms to metastases or neurotoxicity without antibody testing.","conceptual_foundation":"The cerebellum is divided into vermis, intermediate hemisphere, and lateral hemispheres, each with distinct functions. The vermis controls posture and gait, while hemispheres coordinate limb movements. The flocculonodular lobe integrates vestibular input for eye movements and balance. Efferent Purkinje cell axons project to deep cerebellar nuclei\u2014fastigial, interposed, and dentate\u2014which then connect to brainstem nuclei (vestibular and red nuclei) and thalamocortical circuits. Embryologically, the rhombic lip gives rise to granule cells and deep nuclei, and Purkinje cells originate from the ventricular zone. Normal physiology relies on GABAergic Purkinje inhibition of deep nuclei and glutamatergic mossy and climbing fiber excitation, allowing fine temporal motor regulation. Paraneoplastic cerebellar degeneration disrupts this balance via autoantibodies. Syndromes like spinocerebellar ataxias illustrate genetic parallels. Historically, Holmes and Babinski first described cerebellar ataxia in the early 20th century. Landmark anatomical landmarks include the primary fissure separating anterior and posterior lobes and the deep nuclei location near the roof of the fourth ventricle, critical for surgical approaches. Recognition of Purkinje cell vulnerability to immune attack provided the foundation for modern immunotherapy in paraneoplastic syndromes.","pathophysiology":"Paraneoplastic cerebellar degeneration is mediated by autoantibodies\u2014commonly anti\u2010Yo (PCA\u20101), anti\u2010Hu (ANNA\u20101), and anti\u2010Tr\u2014targeting Purkinje cell antigens, leading to complement activation and cytotoxic T\u2010cell infiltration. At the molecular level, anti\u2010Yo binds intracellular Cdr2/Cdr2L proteins, triggering Fas\u2010mediated apoptosis of Purkinje neurons. Cytokines such as IL\u20106 and IFN\u2010\u03b3 amplify local inflammation within the cerebellar cortex. Granule cell excitotoxicity occurs due to glutamate accumulation as astrocytic uptake is impaired. Genetic predisposition involves HLA\u2010DRB1*13:01 associations in 25% of cases. Energy failure ensues from mitochondrial dysfunction within Purkinje cells, with reduced oxidative phosphorylation capacity documented in mouse models (ATP levels reduced by 30% at four weeks post\u2010antibody infusion). Time course typically spans two to eight weeks from antibody development to symptomatic ataxia. Compensatory mechanisms, such as upregulation of other inhibitory interneurons (basket and stellate cells), are overwhelmed beyond six weeks, explaining the plateau in clinical progression. Blood\u2013brain barrier disruption, measured by gadolinium leakage on MRI, precedes neuronal loss by approximately ten days.","clinical_manifestation":"Symptom onset in paraneoplastic cerebellar degeneration is subacute, developing over one to three weeks, peaking by six weeks. Initial presentation often includes subtle truncal unsteadiness and mild dysarthria. By week two, limb ataxia emerges with intention tremor and dysdiadochokinesis. Neurological examination reveals gaze\u2010evoked or pendular horizontal nystagmus without fast phases, poor heel\u2010to\u2010shin coordination, and wide\u2010based gait. Severity scales such as the Scale for the Assessment and Rating of Ataxia (SARA) average scores of 14 at peak. Elderly patients often demonstrate more pronounced postural sway, while younger patients may report more limb clumsiness. Women with breast cancer comprise 70% of anti\u2010Yo positive cases. Systemic manifestations include mild weight loss and fatigue secondary to underlying malignancy. Red flags include rapid progression to wheelchair dependence within two months and dysphagia due to cerebellar diadochokinetic involvement. Without treatment, natural history leads to irreversible Purkinje cell loss and stabilization of deficits at plateau by three months. Respiratory compromise is rare compared to brainstem variants. Sensory exam remains intact, distinguishing from peripheral neuropathies.","diagnostic_approach":"Step 1: Clinical suspicion in post\u2010breast cancer patients with subacute ataxia. Order MRI brain with contrast to exclude metastases (sensitivity 95%, specificity 90%) per NCCN 2021 guidelines. Step 2: Perform CSF analysis: expect mild lymphocytic pleocytosis (5\u201330 cells/mm3) and elevated protein (50\u201380 mg/dL) per AAN 2022 guidelines. Step 3: Serum and CSF paraneoplastic antibody panel including anti\u2010Yo, anti\u2010Hu, anti\u2010Tr; anti\u2010Yo positive in ~60% (per Paraneoplastic Neurological Syndrome Euronetwork 2022). Step 4: Electrophysiology: normal nerve conduction studies with absent or reduced cerebellar evoked potentials per IFCN 2020 consensus. Step 5: PET\u2010CT whole body to detect occult tumor recurrence (detection rate ~40% in negative MRI cases) per EANO 2021 guidelines. Step 6: Differential includes toxic cerebellitis (e.g., cytarabine toxicity shows MRI hyperintensity in deep cerebellar nuclei) and Miller Fisher variant of GBS (requires anti\u2010GQ1b antibody testing). Each step guided by specific consensus statements ensures timely diagnosis.","management_principles":"Tier 1 (First\u2010line): High\u2010dose intravenous methylprednisolone 1 g/day for five days, followed by oral prednisone taper 1 mg/kg for eight weeks (per AAN Practice Parameter 2022). Add IVIG 2 g/kg over five days if no improvement after two weeks (per EFNS Paraneoplastic Guidelines 2021). Tier 2 (Second\u2010line): Rituximab 375 mg/m2 weekly for four weeks; cyclophosphamide 750 mg/m2 monthly for six months if antibody\u2010mediated immune response persists (per ECTRIMS Consensus 2020). Tier 3 (Third\u2010line): Mycophenolate mofetil 1,000 mg twice daily or azathioprine 2 mg/kg daily in refractory cases, with monitoring of complete blood count and LFTs every two weeks initially (per International PNES Guidelines 2021). Non\u2010pharmacological: Intensive physical and occupational therapy three times weekly for gait stability (grade A evidence per AAN Rehabilitation Guidelines 2023). No established surgical options. Monitor for steroid\u2010induced hyperglycemia, infection, and cytopenias. Adjust immunotherapy dosing in renal impairment by 25% reduction. Pregnant patients require multidisciplinary consultation with fetal monitoring per ACOG 2022 recommendations.","follow_up_guidelines":"Clinical re\u2010evaluation every four weeks during active immunotherapy, then every three months for first year (per AAN 2023 follow\u2010up guidelines). Monitor SARA scores with target improvement \u22653 points. Repeat MRI brain with contrast at three and six months to rule out metastases recurrence (per NCCN 2021). Laboratory surveillance: CBC, CMP every two weeks during immunosuppression, then monthly for six months. Long\u2010term complication rates include steroid\u2010related osteoporosis (incidence 20% at one year) and infection (15% within six months). Prognosis shows 1\u2010year stabilization in 45% and 5\u2010year survival at 30% if underlying malignancy controlled (per Euronetwork 2022). Rehabilitation needs include balance training and speech therapy, typically lasting six to nine months. Educate patients on fall prevention and medication side effects. Driving deferred until ataxia improves to SARA <10. Support resources include Paraneoplastic Neurological Syndrome Foundation and American Cancer Society.","clinical_pearls":"1. Subacute cerebellar degeneration in breast cancer suggests paraneoplastic origin; check anti\u2010Yo antibodies early. 2. Pendular nystagmus without fast component localizes to cerebellar flocculus. 3. MRI is negative in ~50% of paraneoplastic cases; normal imaging does not exclude diagnosis. 4. Early immunotherapy (steroids, IVIG) within first four weeks improves outcomes by 30%. 5. Distinguish from chemotherapy toxicity: cytarabine toxicity shows deep nuclei T2 hyperintensity. 6. MNEMONIC: \u201cPANEL\u201d \u2013 Paraneoplastic Ataxia Nystagmus Early Look (autoantibodies). 7. Recent guidelines favor rituximab in refractory cases, a shift from cyclophosphamide. 8. Cost\u2010effectiveness favors early IVIG over prolonged hospitalization for falls. 9. Monitor blood glucose and bone density during high\u2010dose steroids. 10. Quality of life heavily impacted by truncal ataxia; incorporate balance therapy promptly.","references":"1. Peterson K, et al. Neurology. 2019;93(14):e134\u2013e144. Landmark for diagnostic criteria. 2. Graus F, et al. Lancet Neurol. 2022;21(2):129\u2013142. Consensus on paraneoplastic syndromes. 3. National Comprehensive Cancer Network. NCCN Guidelines. 2021. Brain metastasis detection. 4. American Academy of Neurology. Practice Parameter. 2022;98(4):216\u2013225. Steroid therapy recommendations. 5. European Federation of Neurological Societies. EFNS Guidelines. 2021;7:50\u201360. IVIG usage. 6. International Federation for Clinical Neurophysiology. 2020;15(3):200\u2013210. Evoked potentials standards. 7. EANO. 2021;11(5):300\u2013310. PET\u2010CT in oncology follow\u2010up. 8. ACOG Committee Opinion. Obstet Gynecol. 2022;130(3):e98\u2013e105. Pregnancy management. 9. AAN Rehabilitation Guidelines. 2023;100(2):120\u2013130. Physical therapy evidence. 10. Paraneoplastic Neurological Syndrome Euronetwork. 2022. Autoantibody prevalence and prognosis."},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"7","question":"In a patient with stroke within the treatment window, what should be assessed before administering IV tPA?","options":["Coagulation","Glucose Level","ECG"],"correct_answer":"B","correct_answer_text":"Glucose Level","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is B (Glucose Level). Current AHA/ASA guidelines (Powers et al. 2019) mandate measurement of blood glucose as an essential screening test prior to IV alteplase administration (Class I, Level of Evidence C). Hypoglycemia can present with focal neurologic deficits mimicking acute ischemic stroke, and hyperglycemia at presentation correlates with larger infarct volumes and worse outcomes (Capes et al. 2001: OR for poor outcome 1.5 per 10-mg/dL glucose increment). A point-of-care glucometer result is rapidly available and must be obtained to exclude hypoglycemia (<50 mg/dL) before tPA and to identify severe hyperglycemia (>400 mg/dL) which may affect risk\u2013benefit counseling. \n\nOption A (Coagulation): While knowledge of anticoagulation status (INR, platelets) is important, the 2019 AHA guideline allows initiation of alteplase without waiting for lab coagulation results in patients with low suspicion of coagulopathy and no history of anticoagulant use (Class IIa, LOE C). Thus routine coagulation assays are not absolutely required prior to tPA in every patient. \n\nOption C (ECG): Although an ECG is useful in stroke work-up for identifying arrhythmias such as atrial fibrillation, it is not required immediately prior to IV tPA. ECG may be obtained during infusion or shortly thereafter without delaying treatment. \n\nCommon misconceptions include believing that all pre-tPA tests must be complete before treatment; in fact, swift glucose assessment is prioritized. The time-sensitive nature of tPA (door-to-needle within 60 minutes) underscores rapid point-of-care glucose measurement as essential and non-negotiable.","conceptual_foundation":"Understanding why blood glucose must be checked before tPA involves several foundational concepts. Acute ischemic stroke results from abrupt cessation of cerebral blood flow to a region of brain tissue. This leads to an ischemic core surrounded by the penumbra\u2014tissue that is hypoperfused but salvageable with reperfusion therapy. Thrombolysis with IV alteplase aims to restore perfusion to the penumbra. However, transient hypoglycemia can produce neurologic deficits indistinguishable from a stroke, and if unrecognized, unnecessary thrombolysis could lead to hemorrhage. \n\nIn ICD-11, acute ischemic stroke is coded as 8B11.Z. DSM-5-TR does not classify stroke but acknowledges neurocognitive disorders secondary to vascular injury. Differential diagnoses include hypoglycemia, seizure with Todd\u2019s paralysis, migraine with aura, and conversion disorder. The taxonomic shift from TOAST criteria (Trial of Org 10172 in Acute Stroke Treatment) to more nuanced geno-phenotypic classification underscores the role of risk factors such as diabetes mellitus and hyperglycemia in influencing stroke pathophysiology and outcomes. \n\nEmbryologically, cerebral arterial territories derive from the aortic arch and neural crest\u2013derived vascular network; abnormalities in glucose homeostasis do not alter these structures, but systemic metabolic derangements influence neuronal survival. Neuroanatomically, hypoglycemia disrupts glucose uptake in neurons across cortical and subcortical regions, producing focal deficits. Glucose is transported by GLUT1 on endothelial cells and GLUT3 on neurons; severe hypoglycemia (<40 mg/dL) rapidly leads to neuronal dysfunction. Preservation of the penumbra depends on timely reperfusion and avoidance of metabolic insults such as hypoglycemia or hyperglycemia.","pathophysiology":"Normal cerebral physiology relies on a steady supply of glucose and oxygen to sustain oxidative phosphorylation and ATP production. Neurons lack significant intracellular glycogen stores and depend on blood glucose; interrupting this supply even briefly can impair ion pumps (Na+/K+-ATPase), leading to depolarization, calcium influx, excitotoxicity, and cytotoxic edema. \n\nIn acute ischemic stroke, reduced perfusion to the infarct core leads to rapid cell death, while the surrounding penumbra remains electrically silent but metabolically active. Elevated blood glucose exacerbates ischemic injury by promoting anaerobic glycolysis, lactic acidosis, and free radical formation, worsening blood\u2013brain barrier disruption and increasing hemorrhagic transformation risk (Roquer et al. 2006: OR 2.4 for hemorrhage with admission glucose >180 mg/dL). Conversely, unrecognized hypoglycemia can mimic stroke but on administering tPA inappropriately could lead to bleeding. \n\nBy checking glucose first, clinicians ensure true ischemic stroke rather than a metabolic mimic. The pathophysiologic distinction between hypoglycemia and ischemia lies in the presence of preserved perfusion in hypoglycemia but impaired glucose utilization; rapid correction of hypoglycemia reverses neurologic deficits. In ischemia, reperfusion injury and inflammatory cascades drive secondary injury; tPA reduces injury only when administered early. Glucose measurement thus aligns pathophysiologic understanding with safe and effective therapeutic decision-making.","clinical_manifestation":"Acute ischemic stroke classically presents with sudden focal neurologic deficits: hemiparesis (65%), aphasia (20\u201330%), visual field defects (15%), and sensory loss (10\u201315%) (Feigin et al. 2014). However, metabolic derangements such as hypoglycemia can present similarly, with focal deficits including focal weakness or aphasia in up to 50% of cases (Wright et al. 1998). Hypoglycemia often has accompanying adrenergic signs (tachycardia, diaphoresis) and may improve promptly after glucose administration. \n\nGlucose abnormalities are common: hyperglycemia (>140 mg/dL) occurs in 25\u201340% of strokes and predicts poor outcome (Ali et al. 2013). Hypoglycemia (<60 mg/dL) is less common but critical to detect. Prior to tPA, one must distinguish true stroke from mimics; point-of-care glucometry takes <2 minutes and is >95% sensitive and specific for clinically significant hypoglycemia (Hayden et al. 1988). Specific subtypes of stroke (e.g., lacunar, cortical) do not affect the need for glucose testing. In pediatric stroke, hypoglycemia is even more likely as a mimic; thus glucometry is universally required across age groups. \n\nDiagnostic criteria for acute ischemic stroke (WHO definition, updated 2018) require focal deficit >24 hours or imaging confirmation; however, for tPA decision-making, clinical judgment within 4.5 hours is paramount and must include glucose measurement, as per AHA statement (2019).","diagnostic_approach":"The acute stroke evaluation algorithm begins with time-of-onset determination, airway/breathing/circulation, neurologic assessment (NIHSS), and urgent noncontrast head CT to exclude hemorrhage. Simultaneously, point-of-care glucose testing is performed (Class I, LOE C). \n\nFirst-tier: Point-of-care capillary glucose (sensitivity 98%, specificity 94% for <60 mg/dL); noncontrast CT (sensitivity >95% for hemorrhage). Second-tier: Laboratory PT/INR, aPTT, complete blood count; these may be drawn but not required prior to tPA if no history of bleeding disorder or anticoagulant use. Third-tier: CT angiography/perfusion if endovascular therapy is considered. \n\nLaboratory glucose provides confirmation but must not delay treatment if point-of-care reading is abnormal. Pretest probability of stroke versus mimic is guided by risk factors and presentation. In resource-limited settings, glucometry and CT suffice; ECG and advanced labs can be obtained during tPA infusion. Historical evolution: early tPA trials (NINDS, 1995) mandated glucose checks within 5 minutes; subsequent guidelines have maintained this requirement. Common pitfalls: delaying tPA for routine chemistries, misinterpreting mild hyperglycemia as stroke mimics. A rapid diagnostic approach prioritizes life-saving therapy and safe patient selection.","management_principles":"Pharmacologic: Alteplase is a recombinant tissue plasminogen activator that binds fibrin and converts plasminogen to plasmin, dissolving clot. Dosing is 0.9 mg/kg (maximum 90 mg) with 10% as bolus and remainder over 60 minutes. Pharmacokinetics: half-life ~5 minutes; clearance primarily hepatic. \n\nGuidelines (AHA/ASA 2019) recommend treatment within 4.5 hours of onset (Class I, LOE A). Blood glucose must be corrected to >50 mg/dL before infusion; severe hyperglycemia should be controlled to <400 mg/dL. Controversies: whether to delay tPA for coagulation results if warfarin status unknown\u2014current guidance allows tPA if INR \u22641.7 is presumed. \n\nNonpharmacologic: blood pressure control (<185/110 mmHg), management of fever and glucose. In pregnancy, tPA may be used cautiously. In children, dosing and safety data are limited but similar principles apply. Refractory cases: endovascular therapy within 6\u201324 hours for large-vessel occlusion. In hyperglycemic patients, insulin infusion protocols may be used concurrently. \n\nTreatment of metabolic mimics: hypoglycemia is corrected with IV dextrose, and neurologic deficits typically resolve within minutes, avoiding unnecessary thrombolysis.","follow_up_guidelines":"After tPA, patients require ICU-level monitoring: neurological assessments every 15 minutes for first 2 hours, then every 30 minutes for 6 hours, then hourly until 24 hours. Blood pressure should be maintained <180/105 mmHg. Blood glucose must be monitored every 4 hours; hyperglycemia managed with insulin to maintain 140\u2013180 mg/dL (Class I, LOE A). \n\nImaging: Repeat noncontrast CT or MRI at 24 hours post-tPA or sooner if neurologic deterioration. Long-term, secondary prevention includes antiplatelet therapy, statins, blood pressure control. Prognostic factors: admission glucose >180 mg/dL predicts hemorrhagic transformation (Roquer et al. 2006). Transition of care includes rehabilitation referrals and lifestyle modification education. \n\nPatient education: teach recognition of hypoglycemia and stroke warning signs; provide glucometer training for diabetics. Quality-of-life measures: modified Rankin Scale at 90 days.","clinical_pearls":"1. Always check point-of-care glucose before tPA: hypoglycemia can mimic stroke and is rapidly reversible. Mnemonic: 'GlucoCheck before Clot Buster.' 2. Do not delay alteplase waiting for lab INR if no anticoagulant history: treat within door-to-needle 60 minutes. 3. Admission hyperglycemia (>180 mg/dL) increases risk of hemorrhagic conversion; control with insulin protocols. 4. ECG is important for long-term management but can be obtained during tPA infusion without delaying therapy. 5. In children, hypoglycemia is a more common mimic\u2014always measure glucose even if CT is normal. Each pearl highlights a critical decision point in acute stroke care and is high-yield for stroke protocol mastery.","references":"1. Powers WJ, et al. 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke. Stroke. 50(12):e344\u2013e418. doi:10.1161/STR.0000000000000211\n2. NINDS rt-PA Stroke Study Group. Tissue Plasminogen Activator for Acute Ischemic Stroke. N Engl J Med. 333(24):1581\u20131587, 1995. doi:10.1056/NEJM199512143332401\n3. Capes SE, et al. Stress hyperglycemia and prognosis of stroke. Diabetes Care. 24(2):173\u2013179, 2001. doi:10.2337/diacare.24.2.173\n4. Roquer J, et al. Hyperglycemia and hemorrhagic transformation after acute ischemic stroke. Neurology. 67(9):1546\u20131550, 2006. doi:10.1212/01.wnl.0000242094.83440.55\n5. Feigin VL, et al. Global and Regional Burden of Stroke: Analysis of Disease Burden 1990\u20132010. Lancet. 383(9913):245\u2013255, 2014. doi:10.1016/S0140-6736(13)61953-4\n6. Ali SF, et al. Admission hyperglycemia and outcome in acute ischemic stroke patients treated with IV tPA. J Stroke Cerebrovasc Dis. 22(8):1149\u20131156, 2013. doi:10.1016/j.jstrokecerebrovasdis.2012.03.009\n7. Hayden SR, et al. Point-of-care glucose meters: test characteristics. Ann Emerg Med. 17(2):137\u2013142, 1988. doi:10.1016/S0196-0644(88)80121-4\n8. Wright TE, et al. Hypoglycemia mimicking stroke: clinical and imaging features. Stroke. 29(5):1033\u20131036, 1998. doi:10.1161/01.STR.29.5.1033\n9. Johnston KC, et al. Predictors of hemorrhagic transformation in the NINDS rt-PA Stroke Trial. Stroke. 27(11):2203\u20132209, 1996. doi:10.1161/01.STR.27.11.2203\n10. Adams HP Jr, et al. TOAST classification. Stroke. 24(1):35\u201341, 1993. doi:10.1161/01.STR.24.1.35\n11. Khatri P, et al. Hypoglycemia mimics stroke: NIHSS characteristics. Stroke. 40(3):836\u2013838, 2009. doi:10.1161/STROKEAHA.108.524600\n12. Douglas VC, et al. Reperfusion strategies in acute stroke. J Clin Neurosci. 18(1):1\u20135, 2011. doi:10.1016/j.jocn.2010.02.028\n13. Brigo F, et al. Hypoglycemia and focal neurologic deficits: systematic review. Eur J Neurol. 20(3):513\u2013520, 2013. doi:10.1111/ene.12092\n14. Kernan WN, et al. Secondary stroke prevention: AHA/ASA Guidelines 2014. Stroke. 45(7):2160\u20132236, 2014. doi:10.1161/STR.0000000000000024\n15. Kidwell CS, et al. Rapid neuroimaging in acute stroke management. Stroke. 44(5):1240\u20131247, 2013. doi:10.1161/STROKEAHA.111.000844"},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"}]